Table 2.
Characteristic | Range | Reflexology (N = 95)
|
Lay Foot Manipulation (N = 95)
|
Control (N = 96)
|
|||
---|---|---|---|---|---|---|---|
X̄ | SD | X̄ | SD | X̄ | SD | ||
Physical functiona | 0–100 | ||||||
Baseline | 55.8 | 27 | 58 | 26.4 | 55.4 | 28.3 | |
Week 5 | 58.1 | 27 | 61.8 | 26.8 | 53.8 | 27.1 | |
Week 11 | 58.8 | 26.4 | 62.7 | 28.5 | 51.9 | 26.5 | |
Fatigueb | 0–10 | ||||||
Baseline | 5.6 | 2.9 | 5.9 | 2.8 | 5.6 | 2.9 | |
Week 5 | 5.9 | 2.8 | 5.4 | 3 | 6 | 2.8 | |
Week 11 | 5.4 | 2.7 | 4.7 | 2.9 | 5.9 | 3.1 | |
Dyspneaa | 0–4 | ||||||
Baseline | 3.1 | 1.2 | 2.9 | 1.4 | 3.1 | 1.2 | |
Week 5 | 3.3 | 1 | 3 | 1.2 | 3 | 1 | |
Week 11 | 3.3 | 0.9 | 3 | 1.3 | 2.9 | 1.1 | |
CES-D scaleb | 0–60 | ||||||
Baseline | 17.8 | 11.3 | 15.3 | 11.3 | 13.4 | 9.9 | |
Week 5 | 16.6 | 10.5 | 13.5 | 10.8 | 12.4 | 9.2 | |
Week 11 | 13.1 | 10.3 | 12.7 | 10.2 | 13.4 | 10.4 | |
Anxietyb | 0–60 | ||||||
Baseline | 39.6 | 13.1 | 34.9 | 11.1 | 34.3 | 12.6 | |
Week 5 | 37.7 | 13.3 | 32.5 | 10.2 | 34.1 | 10.6 | |
Week 11 | 35.4 | 11.1 | 33.3 | 10.7 | 34.1 | 12.1 | |
FACT-B totala | 0–180 | ||||||
Baseline | 95.3 | 19.1 | 93.1 | 20.6 | 96.7 | 19.4 | |
Week 5 | 96 | 20.4 | 98 | 19.3 | 99.4 | 19 | |
Week 11 | 101.1 | 18.3 | 99.7 | 21.5 | 100.4 | 18.7 | |
Painb | 0–10 | ||||||
Baseline | 3.76 | 2.98 | 3.87 | 3.1 | 3.95 | 3.2 | |
Week 5 | 4 | 3.1 | 3.4 | 3.1 | 4.3 | 3.1 | |
Week 11 | 3.2 | 3.1 | 3.2 | 3 | 3.9 | 3.1 | |
Nauseaa | 0–4 | ||||||
Baseline | 3.29 | 1.04 | 3.03 | 1.27 | 3.14 | 1.14 | |
Week 5 | 3.5 | 0.9 | 3.4 | 1 | 3.4 | 1 | |
Week 11 | 3.5 | 1 | 3.6 | 1 | 3.3 | 1 |
Higher scores indicate better outcomes.
Lower scores indicate better outcomes.
CES-D—Center of Epidemiologic Studies–Depression; FACT-B—Functional Assessment of Cancer Therapy–Breast scale, version 4
Note. Sample sizes were: baseline (reflexology: N = 95; lay foot manipulation: N = 95; control: N = 96), week 5 (reflexology: N = 75; lay foot manipulation: N = 76; control: N = 71), and week 11 (reflexology: N = 71; lay foot manipulation: N = 67; control: N = 63).